Emulsion-based adjuvants for influenza vaccines

References

• Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost–benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA284(13), 1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Weksler ME, Szabo P. The effect of age on the B-cell repertoire. J. Clin. Immunol.20(4), 240–249 (2000).
   PubMed Web of Science ®Google Scholar
• Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol.172(6), 3437–3446 (2004).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine24(16), 3063–3065 (2006).
   PubMed Web of Science ®Google Scholar
• de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol.61(1), 94–99 (2000).
   PubMed Web of Science ®Google Scholar
• Wood JM. Developing vaccines against pandemic influenza. Philos. Trans. R. Soc. Lond. B Biol. Sci.356(1416), 1953–1960 (2001).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Evans TG, McElrath MJ, Matthews T et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine19(15–16), 2080–2091 (2001).
   PubMed Web of Science ®Google Scholar
• Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix™]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs22(5), 279–292 (2008).
   PubMed Web of Science ®Google Scholar
• Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine17(20–21), 2517–2527 (1999).
   PubMed Web of Science ®Google Scholar
• Sambhara S, Woods S, Arpino R et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J. Infect. Dis.177(5), 1266–1274 (1998).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology259(2), 256–261 (1999).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol.176(10), 6333–6339 (2006).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124(4), 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Geeraedts F, Goutagny N, Hornung V et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog.4(8), e1000138 (2008).
   PubMed Web of Science ®Google Scholar
• Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl Acad. Sci. USA104(1), 246–251 (2007).
   PubMed Web of Science ®Google Scholar
• Francis T, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced influenza A. J. Clin. Invest.24(4), 536–546 (1945).
   PubMed Web of Science ®Google Scholar
• Potter CW, Jennings R. Effect of priming on subsequent response to inactivated influenza vaccine. Vaccine21(9–10), 940–945 (2003).
   PubMed Web of Science ®Google Scholar
• Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene. Proc. Natl Acad. Sci. USA96(4), 1651–1656 (1999).
   PubMed Web of Science ®Google Scholar
• Goji NA, Nolan C, Hill H et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis.198(5), 635–641 (2008).
   PubMed Web of Science ®Google Scholar
• Freund J. The mode of action of immunologic adjuvants. Adv. Tuberc. Res.7, 130–148 (1956).
   Google Scholar
• Salk JE, Laurent AM. The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions. J. Exp. Med.95(5), 429–447 (1952).
   PubMed Web of Science ®Google Scholar
• Perkins FT. Experience in the United Kingdom with oil adjuvant influenza vaccines. Ann. Allergy30(5), 288–291 (1972).
   PubMedGoogle Scholar
• Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines1(1), 111–118 (2002).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine13(16), 1557–1562 (1995).
   PubMed Web of Science ®Google Scholar
• Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine18(5–6), 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Ott G, Radhakrishnan R, Fang J-H, Hora M. The adjuvant MF59: a ten year perspective. In: Vaccine Adjuvants: Preparation, Methods and Research Protocols. O’Hagan D(Ed.). Humana Press, NY, USA 211–228 (2000).
   Google Scholar
• Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol.180(8), 5402–5412 (2008).
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA105(30), 10501–10506 (2008).
   PubMed Web of Science ®Google Scholar
• Cataldo DM, van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine15(16), 1710–1715 (1997).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17(23–24), 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol.17(2), 135–140 (2001).
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J. Clin. Immunol.27(5), 542–547 (2007).
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Durando P et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A (H3N2) drifted influenza viruses. Vaccine26(12), 1525–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357(9272), 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine21(15), 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191(8), 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis.197(5), 667–675 (2008).
   PubMed Web of Science ®Google Scholar
• Vesikari T. Higher immunogenicity of a MF59 adjuvanted influenza vaccine compared to a conventional split vaccine in children aged 6 to <36 months. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007 (Abstract G-1247b).
   Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines6(5), 699–710 (2007).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE3(2), e1665 (2008).
   PubMed Web of Science ®Google Scholar
• Baras B, Bouveret N, Devaster J-M et al. A manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir. Viruses2(6), 241–250 (2009).
   Google Scholar
• Chu DW, Dramé M, Hwang SJ et al. Safety and immunogenicity of an AS adjuvanted H5N1 prepandemic influenza vaccine, a Phase III study in a large population of asian adults. Presented at: X International Symposium on Respiratory Viral Infections. Singapore City, Singapore, 28 February–3 March 2008.
   Google Scholar
• Schwarz T, Horacek T, Knuf M et al. A single booster dose 6 months after one or two primary doses of AS03-adjuvanted vaccine induces strong and rapid seroprotective immune responses against both homologous and heterologous H5N1 strains. Vaccine (Epub ahead of print) (2009).
   Google Scholar
• Ballester A, Gárces-Sánchez M, Planelles Cantarino M et al.Immunogenicity evaluation of an AS03-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3–9 years. Presented at: 48th ICAAC (American Society for Microbiology)/46th ISDA (Infectious Diseases Society of America) Annual Joint Meeting. Washington, DC, USA, 25–28 October 2008.
   Google Scholar
• Bigger J, Ruat C, Vasconcelos D, Legastelois I, Stark G, Caillet C. A new adjuvanted low-dose candidate pandemic influenza A (H5N1) vaccine protects ferrets against homologous clade 1 viral challenge and induces clade 2 cross-reactive antibodies. Presented at: Bangkok International Conference on Avian Influenza 2008: Integration from Knowledge to Control. Bangkok, Thailand, 23–25 January 2008.
   Google Scholar
• Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J. Virol.82(5), 2565–2569 (2008).
   PubMed Web of Science ®Google Scholar
• Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis.198(5), 642–649 (2008).
   PubMed Web of Science ®Google Scholar
• Page WF, Norman JE, Benenson AS. Long-term follow-up of army recruits immunized with Freund’s incomplete adjuvanted vaccine. Vaccine Res.2, 141–149 (1993).
   Google Scholar
• Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol.13(9), 1010–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine26(26), 3209–3222 (2008).
   PubMed Web of Science ®Google Scholar
• Rümke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine26(19), 2378–2388 (2008).
   PubMed Web of Science ®Google Scholar
• Ballester A, Gárces Sánchez M, Planelles Cantarino MV et al. Pediatric safety evaluation of an AS-adjuvanted H5N1 vaccine in children aged 6–9 years: a Phase II study. Presented at: 26th Annual Meeting of the European Society ofInfectious Disease. Graz, Austria, 13–17 May 2008.
   Google Scholar
• Heijmans S, De Meulemeester M, Reynders P et al. AS03 adjuvanted prepandemic influenza vaccine: high immunogenicity in the elderly. Presented at: 2nd Vaccine Congress. Boston, MA, USA, 7–9 December 2008.
   Google Scholar
• Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine26(4), 552–561 (2008).
   PubMed Web of Science ®Google Scholar